NBOMe-escaline

NBOMe-escaline, also known as escaline-NBOMe or as N--4-ethoxy-3,5-dimethoxyphenethylamine, is a serotonin receptor agonist and putative psychedelic drug of the phenethylamine, scaline, and N-benzylphenethylamine families. It is the N- derivative of escaline.
The drug acts as a potent serotonin 5-HT_2A receptor partial agonist, with an affinity of 0.537nM, an activational potency of 7.08nM, and an intrinsic activity of 48%. As a serotonin 5-HT_2A receptor agonist in vitro, it was 7-fold more potent than NBOMe-mescaline, 50-fold more potent than escaline, and 476-fold more potent than mescaline.
NBOMe-escaline was first described in the scientific literature by Heinz Pertz and colleagues by 1999. Along with NBOMe-mescaline, it was one of the first psychedelic N-benzylphenethylamines to be discovered, slightly preceding the publication of 25-NB drugs like 25I-NBOMe by the same group of researchers. NBOMe-escaline is not a controlled substance in Canada as of 2025.